

RESEARCH ARTICLE

Open Access

Pneumococcal and influenza immunization in asplenic persons: a retrospective population-based cohort study 1990-2002

Joanne M Langley^{1,2,3,5*}, Linda Dodds^{1,2,3,4}, Deshayne Fell⁴, G Ross Langley³

Abstract

Background: Splenectomy is associated with increased risk for bacteremia, due to impaired clearance of bloodborne agents and to altered phagocytosis and humoral immunity. We conducted a retrospective cohort study of patients at risk for splenectomy for a 13-year period to determine immunization coverage, and outcomes of those with and without splenectomy, and with or without receipt of influenza or pneumococcal vaccine.

Methods: Data were extracted from the provincial Medical Services Insurance database for insured services rendered by a physician for 1990-2002, and from the Vital Statistics Death database. The eligible cohort was selected based on diagnostic codes for hematologic conditions for which splenectomy might be considered, such as immune thrombocytopenia. Each patient was followed longitudinally from the date of first diagnosis until 31Dec2002, or death, or relocation out-of province. In addition, persons with splenectomy and no hematologic condition were identified and followed for 6 months post-surgery. Infectious illness rates per 100 person-years of observation and death rates were calculated with and without splenectomy. Death rates were determined using splenectomy status as a time-dependent covariate. The relationship between splenectomy and death according to immunization status was examined using Cox proportional hazard ratios.

Results: Of 38,812 persons in the cohort 427 subjects with a hematologic diagnosis had splenectomy and another 452 subjects without a hematologic diagnosis had this surgery. 72% were > 18 years of age. Pneumococcal immunization was recorded in 16.5% of asplenic patients overall, and was not associated with reduced risk of death in these persons (adjusted Hazard Ratio [HR] = 1.07, 95% CI 0.70 - 1.65). Influenza immunization was recorded in 53.1% of asplenic patients overall, and was associated with reduced risk of death (adjusted HR = 0.46, 0.33-0.62). No pneumococcal or influenza immunization was recorded in patients with a hematologic diagnosis without splenectomy. Infectious illness visits were higher among all patients who had a splenectomy than among those without a splenectomy (151 visits/100 person-years of observation in the post-splenectomy period vs. 120 visits/100 person-years; $p < 0.0001$).

Conclusions: In asplenic patients, influenza immunization is associated with a 54% reduced risk of death compared to unimmunized asplenic persons; no reduction in risk was demonstrated with (polysaccharide) pneumococcal vaccine. Vaccine coverage in the entire cohort was less than routinely recommended. Improved delivery of infection prevention programs to this population is warranted. Conjugate pneumococcal vaccines should be urgently studied in this immunocompromised population.

* Correspondence: jmlangle@dal.ca

¹Department of Pediatrics, Dalhousie University, IWK Health Centre, 5850 University Avenue, Halifax Nova Scotia, B3K 6R8, Canada

Background

Splenectomy is associated with increased risk for bacteremia due to impaired clearance of bloodborne agents, and to altered phagocytosis and humoral immunity[1-4]. The spleen is also the main site of immunoglobulin M synthesis, and low levels of the opsonins tuftsin and properdin have been reported post-splenectomy [5]. In a review of 78 studies with 19 680 asplenic patients, 3.2% developed invasive infection and the overall mortality was 1.4% [6]. For those who develop fulminant, overwhelming post-splenectomy sepsis, mortality rates approach 50% [7], and those who survive may be left with significant morbidity. *Streptococcus pneumoniae* is the most common etiology of serious infection in this population[8], but illness due to other encapsulated organisms such as *Haemophilus influenzae* and *Neisseria meningitidis*, occurs.

Although infection prevention strategies such as immunization, antibiotic prophylaxis and early care for febrile illness have been recommended for asplenic patients for decades, implementation is often not optimal [8-15]. Life-threatening infectious complications of splenectomy continue to occur. Accordingly, we reviewed outcomes of a province-wide cohort of patients who had health conditions for which splenectomy might be considered or indicated over a 13-year period to determine vaccine coverage rates, if patients with splenectomy have different infection and mortality rates than patients without splenectomy, and whether immunization was associated with better outcomes.

Methods

Data sources

A population-based retrospective cohort was assembled by linking several comprehensive provincial health databases. Nova Scotia is a province in Eastern Canada with a population of ~ 900,000. All residents have a unique health card number which is used to track health services in the universal health care system, to reimburse providers and to track persons moving in and out of the province. The cohort consisted of all persons resident in the province from 1990-2002, who had health conditions for which splenectomy might be considered or indicated.

Data were extracted from the Nova Scotia Medical Services Insurance (MSI) database for insured services rendered by a physician for 1990-2002 and from the provincial Vital Statistics Death Database. The MSI database is a single comprehensive administrative database for health services. All physicians and all residents in the province for more than three months were participants in the health insurance plan. Recording and reporting of services given was the only method of

physician remuneration in this largely fee-for-service system and regular ongoing auditing confirms services are given. The cohort of persons at risk for splenectomy was selected by identifying all International Classification of Diagnostic Codes - 9th Clinical Modification 9 (ICD-CM9) for health conditions for which splenectomy might be considered or indicated. These codes were grouped into five categories, and all patients with a first field diagnostic code for at least one of the following categories were included: immune thrombocytopenia (ITP), Hodgkin's disease, non-Hodgkin lymphoma, haemolytic anemia, or hypersplenism.

Other variables extracted included the following: birth date, diagnosis and service(s), immunizations delivered, whether a splenectomy was performed and the date of surgery, physician visits for which an infectious disease code was used ("infectious illness visit"), and, if applicable, moving out of the province or death. Antibiotic use was not recorded in these datasets. Each patient was followed from the date of first diagnosis until 31 Dec 2002, or death, or relocation out-of province. In addition, an extraction was completed for patients who had a splenectomy during the same time period but did not have one of the aforementioned health conditions. These asplenic persons were assumed to have had a splenectomy on a non-elective basis. The codes for these concurrent events were diverse and included trauma and other surgeries. An arbitrary time period of 6 months was selected to follow health outcomes post-splenectomy.

The conjugate heptavalent pneumococcal vaccine Prevnar[®] was brought into routine immunization programs between 2001 and 2003 in Canada and therefore it is assumed that the 23-valent pneumococcal polysaccharide vaccine was the only pneumococcal vaccine used to immunize the population in this study. The influenza vaccine used in Canada is a trivalent inactivated injectable formulation.

Statistical analysis

The outcome measures of interest were the number of patients living with asplenia (in order to plan health care program delivery), the immunization history of asplenic persons compared to those without splenectomy, and the incidence of infectious illness visits and death in these high risk persons according to immunization status and splenectomy.

Categorical and continuous variables were analyzed using descriptive statistics. Median, 25th and 75th percentiles were used where variables were not normally distributed. In the case of cell counts less than five, the numbers are not reported.

Infectious illness rates were expressed per 100 person-years of observation in persons with splenectomy and

without splenectomy. Rates of death were calculated per 1,000 person years of observation, by splenectomy status and by immunization status. The relationship between splenectomy and death was assessed using Cox proportional hazards regression models (adjusted and unadjusted) using a time-dependent covariate approach whereby the follow-up time for subjects with splenectomy is divided into pre-and post-splenectomy. The relationship between any pneumococcal or influenza immunization and death was evaluated using standard survival analysis among the subset of subjects who had a splenectomy. Survival curves were adjusted for age at diagnosis, gender and diagnostic category. The “end date” for the study was assigned using the termination date if the subject moved or died, or the end of the study period (31 December 2002).

All analyses were performed using SAS (SAS Institute Inc., Cary NC).

The study protocol was approved by the Research Ethics Boards of the IWK Health Centre and the Capital Health District, Halifax, Nova Scotia and by the Privacy Officer of the Nova Scotia Department of Health.

Results

Demographics

The total cohort of patients with hematologic diagnoses of interest and with splenectomy but no pre-existing

hematologic diagnosis consisted of 38,812 patients; 72% were >18 years of age (n = 28,096). Females comprised 57% of the cohort (22,095/38,812). The most common hematologic diagnosis was hypersplenism (78% of children, 44% of adults) followed by ITP (11% of children, 23% of adults). Splenectomy occurred in 427 patients with a hematologic diagnosis in the cohort (1.2%), and in another 452 subjects without a hematologic diagnosis (431 adults; 21 children). Thus over the 13 years, 879 patients, or about 68 persons each year, had splenectomy. Characteristics of the asplenic patients are seen in Table 1.

Splenectomy was most commonly performed for ITP (4.04 splenectomies/1000 person years). Rates for other hematologic conditions were hemolytic anemia (3.63/1000 person years), Non-Hodgkins lymphoma (2.84/1000 person-years), Hodgkin’s disease (1.32/1000 person years) and hypersplenism (0.40/1000 person-years).

Vaccine coverage

Immunization against *Streptococcus pneumoniae* was recorded in 16.5% (n = 132) of all asplenic patients, but not recorded in any patients with a hematologic diagnosis without splenectomy (Figure 1). Influenza immunization was recorded in 53.1% (467/879) of asplenic patients, and 140 patients had at least one influenza vaccination, 79 had two, 62 had 3, 52 had 4, 49 had 5, 48

Table 1 Characteristics of 879 asplenic patients

Characteristic	Total		Pre-existing hematologic diagnosis for which splenectomy could be considered							No pre-existing hematologic diagnosis				
	n = 879 (100%)		ITP (22.3%)		Hodgkins disease (1.0%)		Non-Hodgkins lymphoma (10.1%)		Hemolytic anemia (6.3%)		Hypersplenism (8.9%)		n = 452 (51.4%)	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Age at splenectomy														
≤ 18 years	65	7.4	12	6.1	†		†		19	34.6	11	14.1	21	4.7
> 18 years	814	92.6	184	93.9				36	65.4	67	85.9	431	95.3	
Gender														
Male	471	53.6	79	40.3	†		54	60.7	27	49.1	41	52.6	265	58.6
Female	408	46.4	117	56.7			35	39.3	28	50.9	37	47.4	187	41.4
Death														
Yes	230	26.2	39	19.9	†		28	31.5	13	23.6	12	15.4	135	29.9
No	649	73.8	157	80.1			61	68.5	42	76.4	66	84.6	317	70.1
Any vaccination for influenza														
Yes	467	53.1	123	62.8	†		49	55.1	39	70.9	41	52.6	210	46.5
No	412	46.9	73	37.2			40	44.9	16	29.1	37	47.4	242	53.5
Any vaccination for <i>S.pneumoniae</i>														
Yes	145	16.5	42	21.4	†		12	13.5	16	29.1	21	26.9	53	11.7
No	734	83.5	154	78.6			77	86.5	39	70.9	57	73.1	399	88.3

ITP = immune thrombocytopenic purpura

† Numbers suppressed due to cell size < 5




Figure 1 Percentage of patients with immunization according to splenectomy status, Province of NS 1990-2002. HD = Hematologic disorder.

had 6, 24 had 7, 7 had 8, and 9 had 4 influenza vaccines. The median number of patients receiving both vaccines was 137. Both forms of immunization were recorded more frequently among asplenic patients with a pre-existing hematologic condition than in those without a pre-existing hematologic condition.

Outcomes

Infectious illness visits (IIV) were higher among all patients who had a splenectomy than among those without a splenectomy (151 visits/100 person-years of observation in the post-splenectomy period vs. 120 visits/100 person-years; $p < 0.0001$). Among subjects who had a splenectomy, IIV were decreased in the period post-splenectomy compared to the period before splenectomy for all subgroups except among those patients with ITP. In the period before surgery, overall the rate of IIV was 265 per 100 person years of observation, whereas post-surgery the rate of IIV was 151 per 100 person years of observation.

Among subjects with a hematologic condition, results from Cox proportional hazards regression models, in which splenectomy was modeled as a time-dependent covariate, indicated that the risk of death was significantly higher for patients who underwent splenectomy compared with those who did not (Table 2).

In subgroup analysis the HR for the association between splenectomy and death was not different for conditions which were considered malignant (Hodgkins disease, non-Hodgkins lymphoma) compared to those considered non-malignant conditions (ITP, hemolytic

anemia, hypersplenism): was 1.74 (1.22-2.48). v. 1.75 (1.36-2.54).

Among asplenic subjects, pneumococcal immunization, adjusted for age at diagnosis, gender and diagnostic category, was associated with a reduced risk of death when the effect of influenza vaccine was not considered (Hazard Ratio [HR] 0.68, 95% CI 0.47-1.00). However, no protective effect of pneumococcal vaccine was observed when the analysis was adjusted for the effect of influenza vaccination: HR 1.07 (95% CI 0.70-1.65).

The risk of death was reduced among those asplenic persons who had at least one influenza vaccine: HR (adjusted for pneumococcal vaccine) 0.46 (95% CI 0.33-0.62). In subgroup analysis this effect was seen in ITP, hemolytic anemia, and splenectomy without a pre-existing hematologic diagnosis, but not in the other groups (Table 3).

The hazard ratio for the association between influenza immunization and death for the non-malignant group is 0.35 (0.21-0.58) and for the malignant subgroup is 0.48 (0.22-1.04). For pneumococcal immunization these HRs are 0.32 (0.17-0.58) in the non-malignant subgroup and 0.49 (0.22-1.10) for the malignant group.

Figure 2 presents the survival curve of the relationship between death and influenza immunization in immunized and unimmunized persons with splenectomy and any hematologic condition.

Discussion

This study shows a 53% reduced risk of death in asplenic persons who received influenza immunization

Table 2 Hazards ratios (HR) and 95% confidence intervals (CI) for the relationship between splenectomy (Vs. no splenectomy) and death among subjects with a hematologic condition*

Diagnosis category	Death rates (per 1000 person-years)		HR, 95% CI [†]
	Splenectomy	No splenectomy	
ITP	36.28	26.21	1.57, 1.08-2.29
Hodgkins disease	57.98	26.61	6.47, 2.83-14.81
Non-Hodgkins lymphoma	75.30	56.29	1.58, 1.05-2.39
Hemolytic anemia	45.18	21.80	3.40, 1.76-6.57
Hypersplenism	19.68	5.05	1.16, 0.59-2.26
Overall (all patients with a hematologic condition) ‡	39.65	15.34	1.75, 1.37-2.24

ITP = immune thrombocytopenic purpura

* Rates and HR calculated using the time-dependent covariate approach where follow-up time for subjects with splenectomy is divided into pre- and post-splenectomy

† Adjusted for age at diagnosis and gender.

‡ Adjusted for age at diagnosis, gender and diagnostic category.

compared to those who had no record of such immunization; but surprisingly no influence on death was seen for pneumococcal immunization. Overwhelming post-splenectomy infection (OPSI), usually due to *Streptococcus pneumoniae*, is perhaps the best known infectious complication of asplenia and thus pneumococcal immunization is universally recommended. Immunization against other encapsulated organisms such as *H. influenzae* and *Neisseria meningitidis* is also recommended, preferably at least two weeks prior to splenectomy. Annual influenza vaccine, as well as age appropriate immunization, is also considered standard of care.

Receipt of influenza vaccine was associated with reduced risk of death in the whole cohort and in three subgroups (asplenic patients without a hematologic condition, with ITP and with hemolytic anemia). The mechanism of this protection is not clear, and no

randomized controlled trials of influenza vaccine efficacy in asplenic persons have been performed. Asplenic persons are not generally thought to be at increased risk for complicated viral infections, since innate and cell-mediated immunity are intact. However, production of antibody involves interaction between the humoral and cell-mediated immune systems which could be altered in asplenic persons, and cases of serious viral infection in asplenic persons have been reported[16]. The association between influenza infection and secondary bacterial pneumonia is established; this may be the mechanism by which influenza vaccine protects asplenic persons. This protection, if real, is not well studied in this immunocompromised population. Indeed, a Medline search using the MESH terms "influenza vaccines" AND "splenectomy" or "spleen (subheading abnormalities)" back to 1966 revealed many guidelines, but only one human


Table 3 Deaths rates and hazard ratios (HR) with 95% confidence intervals (CI) for the independent relationship between pneumococcal vaccination (vs. no pneumococcal vaccination), and influenza vaccination (vs. no influenza vaccination) and death among asplenic subjects

Diagnosis category	Pneumococcal vaccination			Influenza vaccination		
	Death rates (per 1000 person-years)		HR, 95% CI*	Death rates (per 1000 person-years)		HR, 95% CI*
	Pneumococcal vaccination	No pneumococcal vaccination		Influenza vaccination	No influenza vaccination	
ITP	16.80	32.35	0.91, 0.33-2.54	16.00	52.79	0.36, 0.18-0.74
Hodgkins disease	0.00	53.50	Indeterminate	23.97	74.21	indeterminate
Non-Hodgkins lymphoma	45.77	59.02	1.00, 0.32-3.09	42.59	75.37	0.45, 0.19-1.08
Hemolytic anemia	25.10	38.78	1.89, 0.31-11.44	17.65	84.98	0.10, 0.12-0.55
Hypersplenism	15.77	18.16	3.21, 0.32-32.13	10.16	27.37	0.17, 0.02-1.38
Splenectomy, no pre-existing hematologic diagnosis	41.81	57.21	1.11, 0.61-2.01	39.58	68.43	0.52, 0.34-0.78
Overall (all asplenic patients) †	28.44	45.78	1.07, 0.70-1.65	27.00	61.67	0.46, 0.33-0.62

ITP = immune thrombocytopenic purpura

* Adjusted for age at diagnosis and gender.

† Adjusted for age at diagnosis, gender and diagnostic category.



study of influenza vaccine in persons with splenectomy [17], one in persons with Hodgkin's disease [18] and a letter to the editor [19]. In 62 patients with splenectomy compared to 55 healthy controls, serologic responses met regulatory criteria regardless of the time from splenectomy, with seroprotection outcomes ranging from 62.9 to 90.3%. Our finding of the protective effect of influenza vaccine could be important for improved health for asplenic and hyposplenic persons, and should be confirmed in other studies.

Immunization coverage overall was very low for (16.5% for *S. pneumoniae*) but better for influenza (53.1%). It is unlikely that our finding of poor immunization coverage is restricted to our jurisdiction, as others have noted incomplete physician and patient knowledge of risks and preventive interventions, poor vaccine coverage, and a lack of systematic immunization programs [9-15,20]. If influenza vaccine offers the protection observed in this study, the need for improved delivery of vaccine will be necessary.

There is concern that asplenic persons may demonstrate reduced immunogenicity to vaccines. In a few small studies variable immunogenicity has been demonstrated for polysaccharide vaccines [21-23], but better immune responses were seen for protein conjugate vaccines [24-28]. The pneumococcal polysaccharide vaccine was in use during the time period of the study. The ongoing introduction of highly effective and immunogenic protein conjugate vaccines for *H. influenzae*, *S. pneumoniae* and *N. meningitidis* has the potential to offer asplenic persons both direct and indirect protection from life-threatening infection. Indirect protection of unimmunized older persons against invasive pneumococcal disease has been shown following the introduction of

universal infant immunization with heptavalent protein conjugate *S. pneumoniae* vaccine [29,30]. Little effort has been directed towards investigation of how these vaccines could be best used in asplenic person in order to determine optimum schedules, doses and timing of immunization, and we suggest that it is urgently needed.

There are several limitations to the design of this study. Because health-care utilization data was collected if a patient sought care, patients with health-seeking behaviour may be more likely to be identified with this method than in a prospective study where active surveillance could be performed. However, it should be noted that this would be unlikely to preferentially favor influenza over pneumococcal immunization. As well one of our outcomes was death as determined by a governmental Vital Statistics database, which would not have been subject to any biases. Comprehensive risk factor information is not collected in these datasets and so there may be confounders for splenectomy, physician visits, death and for immunization which could contribute to outcomes but are not controlled for in the analysis. For example, prophylactic antibiotic use, recommended by many authorities for up to five years to life after splenectomy, may be more common in patients who receive immunization from their care providers. Of note, we did control for age at diagnosis, sex, hematologic condition, time since diagnosis and splenectomy status. A further limitation is short follow-up for after splenectomy for persons without hematologic conditions; future studies should ensure follow-up of several years. Finally, this population likely underestimates the burden of infection in asplenic persons, since those with functional asplenia, hyposplenia or congenital asplenia would not have been identified.

In addition to immunization, other preventive interventions are recommended to avoid devastating and life-threatening complications of infection in persons with splenectomy [3,31]. These include early medical attention and antibiotic therapy for infectious illness, antibiotic prophylaxis, patient education about risks associated with infection, travel and animal bites, and wearing an alert bracelet, pendant or card, so that health professionals will be aware of their status. The literature is replete with surveys showing that recommendations for the prevention of infection are often not being followed by health care providers and patients, and that many asplenic patients are not aware of the risk associated with their acquired immunodeficiency [8,9,12,20,32,10,11,15]. An ideal system to ensure compliance with guidelines has not been reported, but a post-splenectomy registry may provide a systematic approach to this population, and could be cost-effective in terms of avoidance of mortality and overwhelming post-splenectomy sepsis [33]. Based on the results of this study, we plan to develop a method for contacting asplenic persons in our province to determine their health education needs, and their willingness to join a registry so that appropriate immunization and other interventions can be offered over time.

Conclusions

In a retrospective population-based cohort study from 1990-2002 of persons with splenectomy, influenza immunization was associated with a 54% reduced risk of death compared to unimmunized asplenic persons. No reduction in risk of death was demonstrated with pneumococcal vaccine. Vaccine coverage for both pneumococcal and influenza vaccines in the entire cohort was less than routinely recommended (16.5% and 53.1% respectively). Improved delivery of infection prevention programs to this population is warranted. Conjugate pneumococcal vaccines should be urgently studied in this immunocompromised population.

Acknowledgements

This project was funded in part by University Internal Medicine Research Foundation, Dalhousie University, Halifax, Nova Scotia. It was presented in part at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, 25-28 October 2008, Washington, DC. This study would not have been possible without the patient and dedicated assistance of Sylvie Smith Ford, Sandra Dares and Twyla Taylor of the Decision Support division of Nova Scotia Medical Services Insurance, Halifax, Nova Scotia.

Author details

¹Department of Pediatrics, Dalhousie University, IWK Health Centre, 5850 University Avenue, Halifax Nova Scotia, B3K 6R8, Canada. ²Department of Community Health & Epidemiology, Dalhousie University, Centre for Clinical Research, 5790 University Avenue, Halifax, NS B3H 1V7, Canada. ³Canadian Center for Vaccinology, IWK Health Centre and Dalhousie University, 5850 University Avenue, Halifax Nova Scotia, B3K 6R8, Canada. ⁴Department of Obstetrics and Gynecology, IWK Health Centre and Dalhousie University, 5850 University Avenue, Halifax Nova Scotia, B3K 6R8, Canada. ⁵Department

of Medicine, Dalhousie University, QEII Health Sciences Centre, Halifax, NS, B3H 2Y9, Canada.

Authors' contributions

GRL conceived the study and obtained the funding. GRL and JML designed the study. LD and DF designed and performed the statistical analysis. JML prepared the manuscript; and all authors contributed to subsequent revisions and approved the final version.

Competing interests

In the past five years none of the authors have received reimbursements, fees, funding, or salary from an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future. None of the authors hold any stocks or shares in an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future. There are no relevant patents to declare. None of the authors have any other financial competing interests. Non-financial competing interests
There are no non-financial competing interests (political, personal, religious, ideological, academic, intellectual, commercial or any other) to declare in relation to this manuscript.

Received: 18 November 2009 Accepted: 22 July 2010
Published: 22 July 2010

References

1. Lutwick LI: **Life threatening infections in the asplenic or hyposplenic individual.** *Curr Clin Top Infect Dis* 2002, **22**:78-96.
2. Spelman D, Buttery J, Daley A, Isaacs D, Jennens I, Kakakios A, Lawrence R, Roberts S, Torda A, Watson DA, et al: **Guidelines for the prevention of sepsis in asplenic and hyposplenic patients.** *Intern Med J* 2008, **38**(5):349-356.
3. Price VE, Blanchette VS, Ford-Jones EL: **The prevention and management of infections in children with asplenia or hyposplenia.** *Infect Dis Clin North Am* 2007, **21**(3):697-710, viii-ix.
4. Cadili A, de Gara C: **Complications of splenectomy.** *Am J Med* 2008, **121**(5):371-375.
5. Lynch AM, Kapila R: **Overwhelming postsplenectomy infection.** *Infect Dis Clin North Am* 1996, **10**(4):693-707.
6. Bisharat N, Omari H, Lavi I, Raz R: **Risk of infection and death among post-splenectomy patients.** *J Infect* 2001, **43**(3):182-186.
7. Holdsworth RJ, Irving AD, Cuschieri A: **Postsplenectomy sepsis and its mortality rate: actual versus perceived risks.** *The British journal of surgery* 1991, **78**(9):1031-1038.
8. Waghorn DJ, Mayon-White RT: **A study of 42 episodes of overwhelming post-splenectomy infection: is current guidance for asplenic individuals being followed?** *J Infect* 1997, **35**(3):289-294.
9. Waghorn DJ: **Overwhelming infection in asplenic patients: current best practice preventive measures are not being followed.** *J Clin Pathol* 2001, **54**(3):214-218.
10. Wilkes A, Wills V, Smith S: **Patient knowledge of the risks of post-splenectomy sepsis.** *ANZ J Surg* 2008, **78**(10):867-870.
11. Grace RF, Mednick RE, Neufeld EJ: **Compliance with immunizations in splenectomized individuals with hereditary spherocytosis.** *Pediatr Blood Cancer* 2009, **52**(7):865-867.
12. Deodhar M, Kakkar N: **An audit of splenectomies in a teaching hospital in North India. Are postsplenectomy guidelines being complied with?** *J Clin Pathol* 2004, **57**(4):407-410.
13. Kotsanas D, Al-Souffi MH, Waxman BP, King RW, Polkinghorne KR, Woolley IJ: **Adherence to guidelines for prevention of postsplenectomy sepsis. Age and sex are risk factors: a five-year retrospective review.** *ANZ J Surg* 2006, **76**(7):542-547.
14. Corbett SM, Rebeck JA, Rogers FB, Callas P, Grindlinger G, Desjardins S, Hebert JC: **Time lapse and comorbidities influence patient knowledge and pursuit of medical care after traumatic splenectomy.** *J Trauma* 2007, **62**(2):397-403.
15. Meerveld-Eggink A, de Weerd O, Rijkers GT, van Velzen-Blad H, Biesma DH: **Vaccination coverage and awareness of infectious risks in patients with an absent or dysfunctional spleen in the Netherlands.** *Vaccine* 2008, **26**(52):6975-6979.

16. Assy N, Gefen H, Schlesinger S, Karim W: **Reactivation versus primary CMV infection after splenectomy in immunocompetent patients.** *Digestive diseases and sciences* 2007, **52**(12):3477-3479.
17. Brydak LB, Machala M, Laguna P, Rokicka-Milewska R: **Antibody response to influenza vaccination in splenectomized patients in Poland.** *Journal of clinical immunology* 2004, **24**(3):225-236.
18. Siber GR, Weitzman SA, Aisenberg AC: **Antibody response of patients with Hodgkin's disease to protein and polysaccharide antigens.** *Reviews of infectious diseases* 1981, **3**(Suppl):S144-159.
19. Doganci L, Gun H: **Splenectomy and viral vaccines.** *The Pediatric infectious disease journal* 1994, **13**(2):163-164.
20. Shatz DV: **Vaccination practices among North American trauma surgeons in splenectomy for trauma.** *J Trauma* 2002, **53**(5):950-956.
21. Landgren O, Bjorkholm M, Konradsen HB, Soderqvist M, Nilsson B, Gustavsson A, Axedorf U, Kalin M, Grimfors G: **A prospective study on antibody response to repeated vaccinations with pneumococcal capsular polysaccharide in splenectomized individuals with special reference to Hodgkin's lymphoma.** *J Intern Med* 2004, **255**(6):664-673.
22. Cherif H, Landgren O, Konradsen HB, Kalin M, Bjorkholm M: **Poor antibody response to pneumococcal polysaccharide vaccination suggests increased susceptibility to pneumococcal infection in splenectomized patients with hematological diseases.** *Vaccine* 2006, **24**(1):75-81.
23. Eber SW, Langendorfer CM, Ditzig M, Reinhardt D, Stohr G, Soldan W, Schroter W, Tchernia G: **Frequency of very late fatal sepsis after splenectomy for hereditary spherocytosis: impact of insufficient antibody response to pneumococcal infection.** *Ann Hematol* 1999, **78**(11):524-528.
24. Balmer P, Falconer M, McDonald P, Andrews N, Fuller E, Riley C, Kaczmarek E, Borrow R: **Immune response to meningococcal serogroup C conjugate vaccine in asplenic individuals.** *Infect Immun* 2004, **72**(1):332-337.
25. Smets F, Bourgois A, Vermeylen C, Brichard B, Slacmuylders P, Leyman S, Sokal E: **Randomised revaccination with pneumococcal polysaccharide or conjugate vaccine in asplenic children previously vaccinated with polysaccharide vaccine.** *Vaccine* 2007, **25**(29):5278-5282.
26. Mikoluc B, Kayhty H, Bernatowska E, Motkowski R: **Immune response to the 7-valent pneumococcal conjugate vaccine in 30 asplenic children.** *Eur J Clin Microbiol Infect Dis* 2008, **27**(10):923-928.
27. Stanford E, Print F, Falconer M, Lamden K, Ghebrehewet S, Phin N, Baxter D, Helbert M, McCann R, Andrews N, et al: **Immune response to pneumococcal conjugate vaccination in asplenic individuals.** *Human vaccines* 2009, **5**(2):85-91.
28. Orthopoulos GV, Theodoridou MC, Ladis VA, Tsousis DK, Spoulou VI: **The effect of 23-valent pneumococcal polysaccharide vaccine on immunological priming induced by 7-valent conjugate vaccine in asplenic subjects with beta-thalassemia.** *Vaccine* 2009, **27**(3):350-354.
29. Haber M, Barskey A, Baughman W, Barker L, Whitney CG, Shaw KM, Orenstein W, Stephens DS: **Herd immunity and pneumococcal conjugate vaccine: a quantitative model.** *Vaccine* 2007, **25**(29):5390-5398.
30. **Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease—United States, 1998-2003.** *Mmwr* 2005, **54**(36):893-897.
31. Davies JM, Barnes R, Milligan D: **Update of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen.** *Clin Med* 2002, **2**(5):440-443.
32. Di Carlo I, Primo S, Pulvirenti E, Toro A: **Should all splenectomised patients be vaccinated to avoid OPSI? Revisiting an old concept: an Italian retrospective monocentric study.** *Hepatogastroenterology* 2008, **55**(82-83):308-310.
33. Woolley I, Jones P, Spelman D, Gold L: **Cost-effectiveness of a post-splenectomy registry for prevention of sepsis in the asplenic.** *Aust N Z J Public Health* 2006, **30**(6):558-561.

Pre-publication history

The pre-publication history for this paper can be accessed here:
<http://www.biomedcentral.com/1471-2334/10/219/prepub>

doi:10.1186/1471-2334-10-219

Cite this article as: Langley et al.: Pneumococcal and influenza immunization in asplenic persons: a retrospective population-based cohort study 1990-2002. *BMC Infectious Diseases* 2010 **10**:219.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

